Literature DB >> 1707852

Effect of variations in peptide sequence on anti-human milk fat globule membrane antibody reactions.

P X Xing1, K Reynolds, G A Pietersz, I F McKenzie.   

Abstract

Monoclonal anti-mucine antibodies BC1, BC2 and BC3 produced using human milk fat globule membrane react with a synthetic peptide p1-24 (PDTRPAPGSTAPPAHGVTSAPDTR) representing the repeating amino acid sequence of the mucin core protein. The minimum epitope recognized by these three monoclonal antibodies (mAb) in p1-24 was contained in the five amino acids APDTR. To analyse the variation of position of the epitope, various modifications of the APDTR sequence were made by synthesizing peptides and testing by direct binding and inhibition enzyme-linked immunosorbent assays. Firstly, peptides p13-32 and C-p13-32, in which the epitope APDTR was placed in the middle instead of the C-terminal as in p1-24, were examined. These peptides had a greater reaction with mAb BC1, BC2 and BC3 compared with the reaction with p1-24. Secondly, A-p1-24 and TSA-p1-24 were made wherein two APDTR epitopes were present--these peptides were shown to bind two IgG antibody molecules. Finally, the contribution of each amino acid in the APDTR epitope was studied using the pepscan polyethylene rods, making all 20 of the amino acid substitutions in each position for SAPDTR (the minimum epitope APDTR with an adjacent amino acid S). In the 120 peptides examined there were some 'permissible' substitutions in A, D and T but not in P or R for BC1 and BC2; there were more 'permissible' substitutions for BC3; different substitution patterns were found with each antibody and some substitutions gave an increased reaction compared with the native peptide SAPDTR. The studies are of value in analysing the reaction of antibodies with epitopes expressed in breast cancer and in determining the antigenicity of synthetic peptides.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1707852      PMCID: PMC1384501     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  13 in total

Review 1.  High molecular weight epithelial mucins as markers in breast cancer.

Authors:  M R Price
Journal:  Eur J Cancer Clin Oncol       Date:  1988-12

2.  Development and characterization of breast cancer reactive monoclonal antibodies directed to the core protein of the human milk mucin.

Authors:  J Burchell; S Gendler; J Taylor-Papadimitriou; A Girling; A Lewis; R Millis; D Lamport
Journal:  Cancer Res       Date:  1987-10-15       Impact factor: 12.701

3.  Monoclonal antibodies reactive with mucin expressed in breast cancer.

Authors:  P X Xing; J J Tjandra; S A Stacker; J G Teh; C H Thompson; P J McLaughlin; I F McKenzie
Journal:  Immunol Cell Biol       Date:  1989-06       Impact factor: 5.126

4.  Reactivity of anti-human milk fat globule antibodies with synthetic peptides.

Authors:  P X Xing; J J Tjandra; K Reynolds; P J McLaughlin; D F Purcell; I F McKenzie
Journal:  J Immunol       Date:  1989-05-15       Impact factor: 5.422

5.  Reassessment of Ellman's reagent.

Authors:  P W Riddles; R L Blakeley; B Zerner
Journal:  Methods Enzymol       Date:  1983       Impact factor: 1.600

6.  A short sequence, within the amino acid tandem repeat of a cancer-associated mucin, contains immunodominant epitopes.

Authors:  J Burchell; J Taylor-Papadimitriou; M Boshell; S Gendler; T Duhig
Journal:  Int J Cancer       Date:  1989-10-15       Impact factor: 7.396

7.  Cloning of partial cDNA encoding differentiation and tumor-associated mucin glycoproteins expressed by human mammary epithelium.

Authors:  S J Gendler; J M Burchell; T Duhig; D Lamport; R White; M Parker; J Taylor-Papadimitriou
Journal:  Proc Natl Acad Sci U S A       Date:  1987-09       Impact factor: 11.205

8.  A highly immunogenic region of a human polymorphic epithelial mucin expressed by carcinomas is made up of tandem repeats.

Authors:  S Gendler; J Taylor-Papadimitriou; T Duhig; J Rothbard; J Burchell
Journal:  J Biol Chem       Date:  1988-09-15       Impact factor: 5.157

9.  Isolation and sequencing of a cDNA coding for the human DF3 breast carcinoma-associated antigen.

Authors:  J Siddiqui; M Abe; D Hayes; E Shani; E Yunis; D Kufe
Journal:  Proc Natl Acad Sci U S A       Date:  1988-04       Impact factor: 11.205

10.  Cognitive features of continuous antigenic determinants.

Authors:  H M Geysen; T J Mason; S J Rodda
Journal:  J Mol Recognit       Date:  1988-02       Impact factor: 2.137

View more
  6 in total

1.  Respiratory mucins: identification of core proteins and glycoforms.

Authors:  D J Thornton; I Carlstedt; M Howard; P L Devine; M R Price; J K Sheehan
Journal:  Biochem J       Date:  1996-06-15       Impact factor: 3.857

2.  MUC1 (EMA) is preferentially expressed by ALK positive anaplastic large cell lymphoma, in the normally glycosylated or only partly hypoglycosylated form.

Authors:  R L ten Berge; F G Snijdewint; S von Mensdorff-Pouilly; R J Poort-Keesom; J J Oudejans; J W Meijer; R Willemze; J Hilgers; C J Meijer
Journal:  J Clin Pathol       Date:  2001-12       Impact factor: 3.411

3.  Immune recognition of linear epitopes in peptide fragments of epithelial mucins.

Authors:  S Briggs; M R Price; S J Tendler
Journal:  Immunology       Date:  1991-08       Impact factor: 7.397

4.  Homology modeling and molecular dynamics simulations of MUC1-9/H-2K(b) complex suggest novel binding interactions.

Authors:  Athanassios Stavrakoudis; Ioannis G Tsoulos; Katalin Uray; Ferenc Hudecz; Vasso Apostolopoulos
Journal:  J Mol Model       Date:  2010-11-16       Impact factor: 1.810

5.  Antigen-antibody interactions: elucidation of the epitope and strain-specificity of a monoclonal antibody directed against the pilin protein adherence binding domain of Pseudomonas aeruginosa strain K.

Authors:  W Y Wong; R T Irvin; W Paranchych; R S Hodges
Journal:  Protein Sci       Date:  1992-10       Impact factor: 6.725

6.  Production of anti-breast cancer monoclonal antibodies using a glutathione-S-transferase-MUC1 bacterial fusion protein.

Authors:  V Apostolopoulos; P X Xing; J A Trapani; I F McKenzie
Journal:  Br J Cancer       Date:  1993-04       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.